Breakthrough Innovations Drive National Leadership in Urology

Kaye Edmonton Clinic: World-class urologic care under one roof

The Division of Urology continues to strengthen its national leadership through the Alberta Centre for Urologic Research and Excellence. Over the past year, investigators secured over $12 million in active external funding, published 46 peer-reviewed articles, and managed 15 active clinical trials. Highlighted by international studies like MUSIC-Screen and prestigious honors like the European Association of Urology Imaging Vision Award, the division drives precision medicine, trains future clinician-scientists, and delivers innovative urologic care to Albertans.

Research by the Numbers

• 46 peer-reviewed publications, including papers published in leading journals such as JAMA Surgery, European Urology, Nature Communications, The Lancet Regional Health – Americas, and Cell Reports. 
• 15+ active clinical trials spanning prostate cancer, bladder cancer, kidney transplantation, men's health, reconstructive urology, and stone disease. 
• 10 prospective research registries and databases supporting long-term urologic research and innovation.
• More than $12 million in active external research funding, including over $4 million awarded to Division investigators as principal investigators. 
• 4,700+ participants enrolled in the Alberta Prostate Cancer Clinical Database and Biorepository, one of Canada's largest prostate cancer research resources.

Together, these achievements reflect the Division's growing impact in advancing urologic research, improving patient outcomes, and attracting investment to Alberta.

Leading Clinical Research and Innovation

Division researchers are leading internationally recognized studies across multiple urologic subspecialties, including:

• MUSIC-Screen, a global randomized trial evaluating micro-ultrasound versus MRI for prostate cancer screening across 25 international sites. 
• MUSIC-AS, an international study examining micro-ultrasound in active surveillance for prostate cancer. 
• P-GAP, a multicentre randomized trial exploring PSMA-guided focal therapy for prostate cancer 
• Novel research in bladder cancer, kidney transplantation, urethral stricture disease, infertility, neurogenic bladder, and kidney stone disease.

These initiatives provide Albertans with access to cutting-edge clinical trials, innovative diagnostics, and evidence-informed care while positioning Alberta as a national leader in urologic innovation. 

Building the Next Generation

The Division remains committed to training future clinician-scientists and health researchers by supporting:

• 14 urology residents
• 2 clinical fellows
• 1 PhD trainee
• 6 summer students

Several trainees also received competitive scholarships and national research awards during the past year.

Recognition and Impact

Division researchers received national and international recognition for their contributions to urologic science. Highlights included the European Association of Urology Imaging Vision Award, recognizing the world's top publication in urologic imaging, and the submission of a novel prostate cancer therapeutic patent, ZNF281 Interfering Molecules. Investigators also continued to expand collaborations in artificial intelligence, precision medicine, and translational research.

Looking Forward

As our research programs continue to grow, the Division of Urology remains committed to advancing discovery, translating innovation into practice, and improving the lives of patients across Alberta and beyond.